版本:
中国

BRIEF-Cascadian Therapeutics’ tucatinib, receives orphan drug designation from FDA

June 8 Cascadian Therapeutics Inc

* Cascadian therapeutics' lead candidate, tucatinib, receives orphan drug designation from fda for treatment of breast cancer patients with brain metastases‍​ Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐